Session Information
Date: Wednesday, June 22, 2016
Session Title: Parkinson's disease: Psychiatric manifestations
Session Time: 12:00pm-1:30pm
Location: Exhibit Hall located in Hall B, Level 2
Objective: To evaluate the effectiveness of LCIG on neuropsychiatric disturbances in advanced Parkinson’s disease (APD) patients.
Background: Neuropsychiatric disorders are prevalent in PD and may be very disruptive. Specific research on the effect of the advanced therapies on these symptoms is needed.
Methods: Consecutive APD patients assigned to LCIG through routine medical practice were included in this observational, prospective, multicenter study. Patients complete visits at baseline, 1, 3, and 6 months after percutaneous endoscopic gastrostomy (PEG) procedure. Neuropsychiatric disturbances were evaluated with Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s disease–Rating Scale (QUIP-RS), Scale for Evaluation of Neuropsychiatric Disorders in Parkinson’s disease (SEND-PD), and Neuropsychiatric Inventory (NPI-Q).
Results: 62 patients, mean age 71.22 years (SD ±6.98), 41.94% men, were included. Mean time since PD diagnostic was 12.8 years (SD±5.85). Mean time with motor fluctuations was 5.46 years (SD±3.93). At the time of analysis, 46 patients had finished their participation in the study. There was a significant improvement in daily Off time [7.43h (SD ±4.01) vs 1.55h (SD ±1.8); p<0.0001] at 6-month follow-up. Improvement was also significant in UPDRS-II [28.72 (SD ±7.63) vs 22.31 (SD ±8.57); p<0.0001], and UPDRS III [26.62 (SD ±10.83) vs 21.65 (SD ±11.61); p<0.0001]. At baseline, mean score for QUIP-RS was 11 (SD ±11.49) vs 3.91 (SD ±6.32) at follow-up (p<0.0001). No significant differences for SEND-PD total score, Psychotic symptoms, or Mood/Apathy subscales were observed, but for Impulse control disorders (ICD) subscale results were 1.46 at baseline and 0.76 at follow up (p=0.002). NPI-Q scores were, respectively, 7.65 vs 5.56 (p=0.015) for severity and 11.15 vs 7.18 (p<0.0001) for distress. 24,2% of patients reported at least one adverse event (AE), 53.8% of them were related to the treatment. The most common AEs were related to gastrostomy. One patient died because sepsis.
Conclusions: Neuropsychiatric disorders, in particular ICD, improved after LCIG treatment in this study. Desensitization of dopaminergic receptors provided by continuous dopaminergic stimulation with LCIG could have a play improving this clinical problem.
To cite this abstract in AMA style:
M.J. Catalan, P. Montero, J. Herreros, J.M. Arbelo, P. Martinez-Martin. Effectiveness of duodenal levodopa/carbidopa infusion gel (LCIG) therapy on the neuropsychiatric disturbances of advanced Parkinson’s disease (EDIS study) [abstract]. Mov Disord. 2016; 31 (suppl 2). https://www.mdsabstracts.org/abstract/effectiveness-of-duodenal-levodopacarbidopa-infusion-gel-lcig-therapy-on-the-neuropsychiatric-disturbances-of-advanced-parkinsons-disease-edis-study/. Accessed May 13, 2025.« Back to 2016 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/effectiveness-of-duodenal-levodopacarbidopa-infusion-gel-lcig-therapy-on-the-neuropsychiatric-disturbances-of-advanced-parkinsons-disease-edis-study/